HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Retrospective analysis of risk factors for deep infection in lower limb Gustilo-Anderson type III fractures.

AbstractBACKGROUND:
Open fractures are among the most severe injuries observed in orthopedic patients. Treating open fractures is difficult because such patients with infections may require multiple operations and amputations. Furthermore, only a few studies have focused on antibiotic prophylaxis in open fractures and evaluated how to cover lost soft tissue to increase the success rate of reconstruction. We evaluated the risk factors for deep infection in lower limb Gustilo-Anderson (G-A) type III fractures.
MATERIALS AND METHODS:
This retrospective study investigated patients who underwent surgical procedures for lower limb G-A type III fractures between January 2007 and January 2017 at our institution. We enrolled 110 patients with 114 lower limb G-A type III fractures (77 G-A type IIIA fractures and 37 G-A type IIIB fractures) who were followed up for at least 2 years. We compared patients presenting infections with those without infections by assessing the following factors: severe contamination, diabetes, smoking, Injury Severity Scale, segmental fracture, location of fracture, G-A classification, damage control surgery, methods of surgery, timing of fixation, combination of antibiotics used, duration of antibiotic prophylaxis, timing of wound closure, and soft-tissue reconstruction failure.
RESULTS:
Eighteen fractures presented deep infections. Compared with patients without infections, patients developing infections differed significantly in terms of severe contamination (P < 0.01), G-A classification (P < 0.01), duration of antibiotic prophylaxis (P < 0.01), timing of wound closure (P < 0.01), and incidence of soft-tissue reconstruction failure (P < 0.01). Skin grafting was associated with significantly higher failure rates than muscle and free flap reconstructions (P = 0.04). Treatment with antibiotics was significantly longer in patients with drug-resistant bacterial infections than in those without infections (P < 0.01).
CONCLUSION:
Early flaps rather than skin grafting should be used to cover G-A type IIIB fractures, because skin grafting resulted in the highest failure rate among soft-tissue reconstructions in open fractures. Longer duration of antibiotic use had a significant impact not only on deep infection rates but also on the presence of drug-resistant bacteria. These findings suggest that prolonged use of antibiotics should be avoided in cases of open fractures.
LEVEL OF EVIDENCE:
Level IV retrospective observational study.
AuthorsTaku Ukai, Kosuke Hamahashi, Yoshiyasu Uchiyama, Yuka Kobayashi, Masahiko Watanabe
JournalJournal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology (J Orthop Traumatol) Vol. 21 Issue 1 Pg. 10 (Jul 18 2020) ISSN: 1590-9999 [Electronic] Italy
PMID32683562 (Publication Type: Journal Article, Observational Study)
Chemical References
  • Anti-Bacterial Agents
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents (administration & dosage, therapeutic use)
  • Antibiotic Prophylaxis
  • Debridement
  • Female
  • Fracture Fixation, Internal (methods)
  • Fractures, Open (complications, drug therapy, surgery)
  • Humans
  • Lower Extremity (injuries, microbiology, surgery)
  • Male
  • Middle Aged
  • Osteomyelitis (etiology, prevention & control, therapy)
  • Plastic Surgery Procedures (methods)
  • Retrospective Studies
  • Risk Factors
  • Soft Tissue Infections (diagnosis, etiology, microbiology, therapy)
  • Soft Tissue Injuries (complications, therapy)
  • Surgical Flaps
  • Surgical Wound Infection (diagnosis, etiology, prevention & control, therapy)
  • Tibial Fractures (drug therapy, microbiology, surgery)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: